Xin Lang Cai Jing·2025-11-24 00:30Core Viewpoint - The collaboration between Heptares Therapeutics and AstraZeneca aims to advance the discovery and development of next-generation biotherapies, including antibody-drug conjugates (ADCs) and T cell engagers (TCEs) [1] Group 1: Collaboration Details - Heptares Therapeutics will update and deepen its global strategic collaboration with AstraZeneca established in March 2025 [1] - AstraZeneca will nominate research and development projects to Heptares annually over the next four years, retaining the option to license these projects [1] - Heptares is eligible to receive option fees, exercise fees, development and commercial milestone payments, as well as tiered royalties based on future net sales of licensed projects [1] Group 2: Financial Terms - The economic terms of the collaboration remain consistent with the financial framework agreed upon by both parties in March 2025 [1]